Douillard JY - Search Results

1

A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.

Etienne-Grimaldi MC, François E, Cardot JM, Renée N, Douillard JY, Gamelin E, Bennouna J, Château Y, Milano G. Etienne-Grimaldi MC, et al. Among authors: douillard jy. Clin Pharmacokinet. 2007;46(11):953-63. doi: 10.2165/00003088-200746110-00003. Clin Pharmacokinet. 2007. PMID: 17922560 Clinical Trial.

2

Update on European adjuvant trials with irinotecan for colorectal cancer.

Douillard JY, Barbarot V, Bennouna J. Douillard JY, et al. Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):13-5. Oncology (Williston Park). 2002. PMID: 12014862 Free article. Review.

3

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE. Douillard JY, et al. J Clin Oncol. 2002 Sep 1;20(17):3605-16. doi: 10.1200/JCO.2002.04.123. J Clin Oncol. 2002. PMID: 12202661 Clinical Trial.

4

Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer.

Bennouna J, Douillard JY. Bennouna J, et al. Among authors: douillard jy. Int J Clin Oncol. 2002 Aug;7(4):236-44. doi: 10.1007/s101470200035. Int J Clin Oncol. 2002. PMID: 12202977 Review. No abstract available.

5

Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy.

Bennouna J, Douillard JY. Bennouna J, et al. Among authors: douillard jy. Expert Rev Anticancer Ther. 2003 Aug;3(4):505-17. doi: 10.1586/14737140.3.4.505. Expert Rev Anticancer Ther. 2003. PMID: 12934662 Review.

6

Repeat hepatectomy for colorectal liver metastases.

Hamy A, Bennouna J, Heymann MF, Douillard JY, Paineau J. Hamy A, et al. Among authors: douillard jy. Int Surg. 2005 Sep-Oct;90(4):189-97. Int Surg. 2005. PMID: 16548313

7

Potential regional differences for the tolerability profiles of fluoropyrimidines.

Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzén F, Twelves C. Haller DG, et al. Among authors: douillard jy. J Clin Oncol. 2008 May 1;26(13):2118-23. doi: 10.1200/JCO.2007.15.2090. J Clin Oncol. 2008. PMID: 18445840

8

Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?

Douillard JY, Bennouna J, Senellart H. Douillard JY, et al. Clin Colorectal Cancer. 2008 May;7(3):206-11. doi: 10.3816/CCC.2008.n.029. Clin Colorectal Cancer. 2008. PMID: 18621641 Review.

9

The role of UFT in metastatic colorectal cancer.

Bennouna J, Saunders M, Douillard JY. Bennouna J, et al. Among authors: douillard jy. Oncology. 2009;76(5):301-10. doi: 10.1159/000209334. Epub 2009 Mar 20. Oncology. 2009. PMID: 19299903 Review.

10

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.

Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY. Bennouna J, et al. Among authors: douillard jy. Invest New Drugs. 2011 Oct;29(5):1021-8. doi: 10.1007/s10637-010-9392-8. Epub 2010 Feb 2. Invest New Drugs. 2011. PMID: 20127139 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

330 results

Search Page